164 related articles for article (PubMed ID: 20108890)
1. Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients.
Lendvai N; Gnjatic S; Ritter E; Mangone M; Austin W; Reyner K; Jayabalan D; Niesvizky R; Jagannath S; Bhardwaj N; Chen-Kiang S; Old LJ; Cho HJ
Cancer Immun; 2010 Jan; 10():4. PubMed ID: 20108890
[TBL] [Abstract][Full Text] [Related]
2. The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation.
Jungbluth AA; Ely S; DiLiberto M; Niesvizky R; Williamson B; Frosina D; Chen YT; Bhardwaj N; Chen-Kiang S; Old LJ; Cho HJ
Blood; 2005 Jul; 106(1):167-74. PubMed ID: 15761016
[TBL] [Abstract][Full Text] [Related]
3. MAGE-C1/CT7 and MAGE-C2/CT10 are frequently expressed in multiple myeloma and can be explored in combined immunotherapy for this malignancy.
de Carvalho F; Alves VL; Braga WM; Xavier CV; Colleoni GW
Cancer Immunol Immunother; 2013 Jan; 62(1):191-5. PubMed ID: 23180015
[TBL] [Abstract][Full Text] [Related]
4. Expression and immune responses to MAGE antigens predict survival in epithelial ovarian cancer.
Daudi S; Eng KH; Mhawech-Fauceglia P; Morrison C; Miliotto A; Beck A; Matsuzaki J; Tsuji T; Groman A; Gnjatic S; Spagnoli G; Lele S; Odunsi K
PLoS One; 2014; 9(8):e104099. PubMed ID: 25101620
[TBL] [Abstract][Full Text] [Related]
5. Expression and prognostic relevance of MAGE-C1/CT7 and MAGE-C2/CT10 in osteolytic lesions of patients with multiple myeloma.
Pabst C; Zustin J; Jacobsen F; Luetkens T; Kröger N; Schilling G; Bokemeyer C; Sauter G; Atanackovic D; Marx A
Exp Mol Pathol; 2010 Oct; 89(2):175-81. PubMed ID: 20621094
[TBL] [Abstract][Full Text] [Related]
6. Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells.
Atanackovic D; Hildebrandt Y; Jadczak A; Cao Y; Luetkens T; Meyer S; Kobold S; Bartels K; Pabst C; Lajmi N; Gordic M; Stahl T; Zander AR; Bokemeyer C; Kröger N
Haematologica; 2010 May; 95(5):785-93. PubMed ID: 20015885
[TBL] [Abstract][Full Text] [Related]
7. MAGE-C1/CT7 is the dominant cancer-testis antigen targeted by humoral immune responses in patients with multiple myeloma.
Curioni-Fontecedro A; Knights AJ; Tinguely M; Nuber N; Schneider C; Thomson CW; von Boehmer L; Bossart W; Pahlich S; Gehring H; Moch H; Renner C; Knuth A; Zippelius A
Leukemia; 2008 Aug; 22(8):1646-8. PubMed ID: 18323799
[No Abstract] [Full Text] [Related]
8. Differential pattern of CD4+ and CD8+ T-cell immunity to MAGE-A1/A2/A3 in patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma.
Goodyear OC; Pratt G; McLarnon A; Cook M; Piper K; Moss P
Blood; 2008 Oct; 112(8):3362-72. PubMed ID: 18658027
[TBL] [Abstract][Full Text] [Related]
9. Cancer-testis antigen 7 expression and immune responses following allogeneic stem cell transplantation for multiple myeloma.
Tyler EM; Jungbluth AA; Gnjatic S; O'Reilly RJ; Koehne G
Cancer Immunol Res; 2014 Jun; 2(6):547-58. PubMed ID: 24894092
[TBL] [Abstract][Full Text] [Related]
10. Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines.
de Carvalho F; Costa ET; Camargo AA; Gregorio JC; Masotti C; Andrade VC; Strauss BE; Caballero OL; Atanackovic D; Colleoni GW
PLoS One; 2011; 6(11):e27707. PubMed ID: 22110734
[TBL] [Abstract][Full Text] [Related]
11. Cancer/Testis Antigen MAGE-C1/CT7: new target for multiple myeloma therapy.
de Carvalho F; Vettore AL; Colleoni GW
Clin Dev Immunol; 2012; 2012():257695. PubMed ID: 22481966
[TBL] [Abstract][Full Text] [Related]
12. Expression of MAGE-C1/CT7 and MAGE-C2/CT10 predicts lymph node metastasis in melanoma patients.
Curioni-Fontecedro A; Nuber N; Mihic-Probst D; Seifert B; Soldini D; Dummer R; Knuth A; van den Broek M; Moch H
PLoS One; 2011; 6(6):e21418. PubMed ID: 21738656
[TBL] [Abstract][Full Text] [Related]
13. Expression of cancer-testis antigen in multiple myeloma.
He L; Ji JN; Liu SQ; Xue E; Liang Q; Ma Z
J Huazhong Univ Sci Technolog Med Sci; 2014 Apr; 34(2):181-185. PubMed ID: 24710929
[TBL] [Abstract][Full Text] [Related]
14. Induction of Humoral and Cellular Immune Responses in Mice by Multiepitope Vaccines Composing of Both T and B Lymphocyte Epitopes of MAGE-A3 which are Recombined into HBcAg.
Chen Q; Li W; Wang P; Shao H; Ding Y; Wang W; Cen D; Cai Y; Xue X; Zhang L; Zhu G
Protein Pept Lett; 2017; 24(10):947-954. PubMed ID: 28641561
[TBL] [Abstract][Full Text] [Related]
15. Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease.
Dhodapkar MV; Osman K; Teruya-Feldstein J; Filippa D; Hedvat CV; Iversen K; Kolb D; Geller MD; Hassoun H; Kewalramani T; Comenzo RL; Coplan K; Chen YT; Jungbluth AA
Cancer Immun; 2003 Jul; 3():9. PubMed ID: 12875607
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma.
Atanackovic D; Luetkens T; Hildebrandt Y; Arfsten J; Bartels K; Horn C; Stahl T; Cao Y; Zander AR; Bokemeyer C; Kröger N
Clin Cancer Res; 2009 Feb; 15(4):1343-52. PubMed ID: 19190130
[TBL] [Abstract][Full Text] [Related]
17. Expression of MAGE-C1/CT7 and selected cancer/testis antigens in ovarian borderline tumours and primary and recurrent ovarian carcinomas.
Zimmermann AK; Imig J; Klar A; Renner C; Korol D; Fink D; Stadlmann S; Singer G; Knuth A; Moch H; Caduff R
Virchows Arch; 2013 May; 462(5):565-74. PubMed ID: 23529156
[TBL] [Abstract][Full Text] [Related]
18. The clinical value of the quantitative detection of four cancer-testis antigen genes in multiple myeloma.
Zhang Y; Bao L; Lu J; Liu KY; Li JL; Qin YZ; Chen H; Li LD; Kong Y; Shi HX; Lai YY; Liu YR; Jiang B; Chen SS; Huang XJ; Ruan GR
Mol Cancer; 2014 Feb; 13():25. PubMed ID: 24499297
[TBL] [Abstract][Full Text] [Related]
19. MAGE-C1/CT7 spontaneously triggers a CD4+ T-cell response in multiple myeloma patients.
Nuber N; Curioni-Fontecedro A; Dannenmann SR; Matter C; von Boehmer L; Atanackovic D; Knuth A; van den Broek M
Leukemia; 2013 Aug; 27(8):1767-9. PubMed ID: 23429573
[No Abstract] [Full Text] [Related]
20. SSX cancer testis antigens are expressed in most multiple myeloma patients: co-expression of SSX1, 2, 4, and 5 correlates with adverse prognosis and high frequencies of SSX-positive PCs.
Taylor BJ; Reiman T; Pittman JA; Keats JJ; de Bruijn DR; Mant MJ; Belch AR; Pilarski LM
J Immunother; 2005; 28(6):564-75. PubMed ID: 16224274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
